This recombinant monoclonal antibody is a research-grade biosimilar to Rituximab-arrx, designed to target MS4A1 (CD20), a transmembrane phosphoprotein exclusively expressed on the surface of B lymphocytes from pre-B to mature B cell stages. MS4A1 plays a critical role in regulating B cell activation, proliferation, and differentiation through modulation of calcium influx and cell cycle progression. This target is clinically significant in B cell-mediated autoimmune disorders and hematological malignancies, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis, where aberrant B cell activity drives disease pathology.
Rituximab-arrx is an FDA-approved biosimilar of the original rituximab therapeutic antibody, which functions by inducing selective B cell depletion through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and direct apoptosis induction. This research-grade biosimilar provides investigators with a valuable tool for studying B cell biology, evaluating immune-mediated disease mechanisms, and developing novel therapeutic strategies targeting CD20-positive cell populations in preclinical models and in vitro experimental systems.
Email: support@cusabio.com
Distributors Worldwide